#National Institute of Allergy and Infectious Diseases

What have we learned from the COVID-19 pandemic, and what’s the future of HIV vaccine research? Find out this #HVAD2022.

The HVTN 302 trial is evaluating experimental vaccines that deliver stabilized HIV spike proteins.

The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV.

New vaccine approach triggers neutralizing antibody production and T-cell responses and lowers risk of infection.

The removal of “AIDS” from the names of two CDC HIV agencies coincides with structural changes.

The National Institutes of Health awarded grants for HIV cure research to these 10 organizations. One focuses on pediatric populations.

AVAC’s theme for HVAD 2021 is “HIV Vaccine Research: Building on Lessons from COVID.”

Abbott researchers found a high proportion of elite HIV controllers in the Democratic Republic of Congo, which could lead to cure insights.

A roll call from team Biden-Harris

The new prevention approach shows promise, but it isn’t heading to the clinic anytime soon.

Here are the researchers who will lead the four networks of HIV trials and what each network will focus on.

While receiving a lifetime achievement award, the infectious disease expert shares memories and insights.

Anthony Fauci, MD, leads U.S. efforts against HIV and COVID-19.

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

Products based on broadly neutralizing antibodies could be used in HIV treatment and prevention.

Funding will support the DC Cohort, the “largest citywide study of people living with HIV in the United States.”